Author(s)

Jingjing Zhang^1*, Dianbin Song², Yi Dong¹, Lu Bai¹, Dongqi Gao¹, Shenglin Zhang¹, Yan Guo¹, Fubo Li¹, Xiaolei Yu¹, Qingshan Li^1#

¹Department of Oncology, The Affiliated Hospital of Chengde Medical University, Chengde, China.
²Department of Urology, The Affiliated Hospital of Chengde Medical University, Chengde, China.

Objective: To analyze the effects of different stages of chemotherapy on the immune cytokines (NKG2D, IL-12, IL-15, IL-18, DC cells, TNF-a, IFN-r) in patients with non-small cell lung cancer (NSCLC). Methods: 106 patients who met the research requirements in the Department of oncology of the Affiliated Hospital of Chengde Medical College from September 2018 to June 2021 were included in the study. The blood levels of interleukin-12 (IL-12), interleukin-15 (IL-15), interleukin-18 (IL-18), dendritic cells (DC cells), tumor necrosis factor A (TNF-a) and the levels of immune interferon (IFN-r) and NK cell activating receptor (NKG2D) in blood before chemotherapy, after the first chemotherapy and after the second chemotherapy were analyzed. Results: Except for the viability of DC cells and DC cells, all other immune factor groups showed statistical differences. Conclusion: Chemotherapy will have a negative effect on all immune factors except DC cells. The effect of immune factors will be weakened according to the increase of the chemotherapy cycle. Therefore, immunotherapy for non-small cell lung cancer needs to be carried out before chemotherapy or in the early stage of chemotherapy to achieve better results.

Non-Small Cell Lung Cancer, Chemotherapy, Immune Cytokines

Zhang, J. , Song, D. , Dong, Y. , Bai, L. , Gao, D. , Zhang, S. , Guo, Y. , Li, F. , Yu, X. and Li, Q. (2021) Effect of Chemotherapy on Immune Factors in Patients with Non-Small Cell Lung Cancer. Journal of Biosciences and Medicines, 9, 110-117. doi: 10.4236/jbm.2021.912009.